Search details
1.
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
Cancer Immunol Immunother
; 72(1): 137-149, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-35771253
2.
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
Br J Cancer
; 126(6): 907-916, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34912074
3.
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Int J Cancer
; 148(2): 385-395, 2021 01 15.
Article
in English
| MEDLINE | ID: mdl-32965028
4.
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Eur J Nucl Med Mol Imaging
; 48(10): 3325-3334, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33686456
5.
The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.
Oncologist
; 25(1): e1-e4, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31488619
6.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Article
in English
| MEDLINE | ID: mdl-28212060
7.
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
Cancer Immunol Immunother
; 69(3): 477-488, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-31980913
8.
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
Clin Chem
; 66(6): 842-851, 2020 06 01.
Article
in English
| MEDLINE | ID: mdl-32408351
9.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Article
in English
| MEDLINE | ID: mdl-32928177
10.
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Future Oncol
; 16(19): 1371-1384, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32469606
11.
Healthcare professionals' perspectives of barriers and facilitators in implementing physical activity programmes delivered to cancer survivors in a shared-care model: a qualitative study.
Support Care Cancer
; 28(7): 3429-3440, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-31792881
12.
Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.
Ann Surg Oncol
; 26(12): 3945-3952, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-30830540
13.
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
Br J Cancer
; 126(7): 1108, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-35210590
14.
Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.
Biomed Chromatogr
; 31(11)2017 Nov.
Article
in English
| MEDLINE | ID: mdl-28370076
15.
mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
Int J Cancer
; 138(10): 2312-21, 2016 May 15.
Article
in English
| MEDLINE | ID: mdl-26452336
16.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
N Engl J Med
; 368(2): 138-48, 2013 Jan 10.
Article
in English
| MEDLINE | ID: mdl-23228172
17.
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
J Transl Med
; 14: 88, 2016 Apr 14.
Article
in English
| MEDLINE | ID: mdl-27075584
18.
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
Int J Cancer
; 136(1): 127-37, 2015 Jan 01.
Article
in English
| MEDLINE | ID: mdl-24832153
19.
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements.
Oncologist
; 25(10): e1428-e1432, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32333623
20.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24831977